93 related articles for article (PubMed ID: 11201987)
1. Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro.
Wang H
Nagoya J Med Sci; 2000 Nov; 63(3-4):129-37. PubMed ID: 11201987
[TBL] [Abstract][Full Text] [Related]
2. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines.
Aoe K; Kiura K; Ueoka H; Tabata M; Matsumura T; Chikamori M; Matsushita A; Kohara H; Harada M
Anticancer Res; 1999; 19(1A):291-9. PubMed ID: 10226557
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
[TBL] [Abstract][Full Text] [Related]
4. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
Le Chevalier T; Bérille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
[TBL] [Abstract][Full Text] [Related]
5. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
Fossella F; Pereira JR; von Pawel J; Pluzanska A; Gorbounova V; Kaukel E; Mattson KV; Ramlau R; Szczesna A; Fidias P; Millward M; Belani CP
J Clin Oncol; 2003 Aug; 21(16):3016-24. PubMed ID: 12837811
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
8. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
Yamamoto N; Nishimura Y; Nakagawa K; Matsui K; Fukuoka M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):285-91. PubMed ID: 16416334
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
[TBL] [Abstract][Full Text] [Related]
11. Study shows 2-year survival advantage for docetaxel.
Expert Rev Anticancer Ther; 2001 Oct; 1(3):323-4. PubMed ID: 12113094
[No Abstract] [Full Text] [Related]
12. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer.
Mattson K; Saarinen A; Jekunen A
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-5-S14-8. PubMed ID: 9335516
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel in the management of advanced non-small cell lung cancer.
Miller VA
Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
[TBL] [Abstract][Full Text] [Related]
14. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
16. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer.
Inoue Y; Gika M; Abiko T; Oyama T; Saitoh Y; Yamazaki H; Nakamura M; Abe Y; Kawamura M; Kobayashi K
Oncol Rep; 2005 Feb; 13(2):259-64. PubMed ID: 15643508
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
19. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
Thongprasert S; Cheewakriangkrai R; Napapan S
J Med Assoc Thai; 2002 Dec; 85(12):1296-300. PubMed ID: 12678167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
